Outbreak News Today
Date: January 11, 2016
By: Press Release

Valneva SE, a leading pure play vaccine company, announced today that vaccine manufacturer Adimmune was granted marketing approval for Valneva’s Japanese encephalitis (JE) vaccine by the Taiwanese Food & Drug Administration (TFDA). The product is expected to be marketed in Taiwan under the trade name JEVAL® .

This approval follows the agreement signed in 2014 between Valneva and Adimmune granting Adimmune the right to commercialize JEVAL® in Taiwan, including the right to locally fill and pack JEVAL® by using bulk product delivered by Valneva.

Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva commented, “The JEVAL® approval is an important step forward in our JE vaccine expansion strategy into endemic markets. Given Adimmune’s leading position as a commercial vaccine manufacturer in Taiwan, we expect strong product supplies in this market, allowing us to leverage our existing manufacturing capacities and significantly contribute to our product profitability.”     [FULL  STORY]